MicroRNAs in nonalcoholic fatty liver disease

Journal of Clinical Medicine

Volumn 4, Issue 12, 2015, Pages 1977-1988

  Baffy, György ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antagomir; Circulating miRNA; Differential expression; Hepatocellular carcinoma; MiRNA; Nonalcoholic fatty liver disease; Predicted target genes; Steatohepatitis; Transcriptome

Indexed keywords

MICRORNA;

CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE SEVERITY ASSESSMENT; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER CELL DAMAGE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84959248478     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4121953     Document Type: Review

References (77)

1. Lazo, M.; Hernaez, R.; Eberhardt, M.S.; Bonekamp, S.; Kamel, I.; Guallar, E.; Koteish, A.; Brancati, F.L.; Clark, J.M. Prevalence of nonalcoholic fatty liver disease in the United States: The third national health and nutrition examination survey, 1988-1994. Am. J. Epidemiol. 2013, 178, 38–45.
2. Satapathy, S.K.; Sanyal, A.J. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin. Liver Dis. 2015, 35, 221-235.
3. Ludwig, J.; Viggiano, T.R.; McGill, D.B.; Oh, B.J. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55, 434-438.
4. Kim, C.H.; Younossi, Z.M. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Clevel. Clin. J. Med. 2008, 75, 721-728.
5. Ahmed, A.; Wong, R.J.; Harrison, S.A. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes. Clin. Gastroenterol. Hepatol. 2015, 13, 2062-2070.
6. Rinella, M.E. Nonalcoholic fatty liver disease: A systematic review. JAMA 2015, 313, 2263-2273.
7. Baffy, G.; Brunt, E.M.; Caldwell, S.H. Hepatocellular carcinoma in nonalcoholic fatty liver disease: An emerging menace. J. Hepatol. 2012, 56,1384-1391.
8. Pocha, C.; Kolly, P.; Dufour, J.F. Nonalcoholic fatty liver disease-related hepatocellular carcinoma: A problem of growing magnitude. Semin. Liver Dis. 2015, 35, 304-317.
9. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346,1221-1231.
10. Anstee, Q.M.; Daly, A.K.; Day, C.P. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin. Liver Dis. 2011, 31,128-146.
11. McCarthy, M.I.; Abecasis, G.R.; Cardon, L.R.; Goldstein, D.B.; Little, J.; Ioannidis, J.P.; Hirschhorn, J.N. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat. Rev. Genet. 2008, 9, 356-369.
12. Manolio, T.A.; Collins, F.S.; Cox, N.J.; Goldstein, D.B.; Hindorff, L.A.; Hunter, D.J.; McCarthy, M.I.; Ramos, E.M.; Cardon, L.R.; Chakravarti, A. et al. Finding the missing heritability of complex diseases. Nature 2009, 461, 747-753.
13. Frazer, K.A.; Murray, S.S.; Schork, N.J.; Topol, E.J. Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 2009,10, 241-251.
14. Eichler, E.E.; Flint, J.; Gibson, G.; Kong, A.; Leal, S.M.; Moore, J.H.; Nadeau, J.H. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 2010, 11, 446-450.
15. Vickers, M.H. Early life nutrition, epigenetics and programming of later life disease. Nutrients 2014, 6, 2165-2178.
16. Bartel, D.P. Micrornas: Genomics, biogenesis, mechanism, and function. Cell 2004,116, 281-297.
17. Mohr, A.M.; Mott, J.L. Overview of microrna biology. Semin. Liver Dis. 2015, 35, 3-11.
18. Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mrnas are conserved targets of micrornas. Genome Res. 2009,19,92-105.
19. Panera, N.; Gnani, D.; Crudele, A.; Ceccarelli, S.; Nobili, V.; Alisi, A. Micrornas as controlled systems and controllers in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20, 15079-15086.
20. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509-524.
21. Lee, H.J. Exceptional stories of microRNAs. Exp. Biol. Med. (Maywood) 2013, 238, 339-343.
22. Wang, X.W.; Heegaard, N.H.; Orum, H. MicroRNAs in liver disease. Gastroenterology 2012,142,1431-1443.
23. Lee, H.J. Additional stories of microRNAs. Exp. Biol. Med. (Maywood) 2014, 239, 1275-1279.
24. Arner, P.; Kulyte, A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat. Rev. Endocrinol. 2015,11, 276-288.
25. Sobolewski, C.; Calo, N.; Portius, D.; Foti, M. MicroRNAs in fatty liver disease. Semin. Liver Dis. 2015, 35, 12-25.
26. Ferreira, D.M.; Simao, A.L.; Rodrigues, C.M.; Castro, R.E. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J. 2014, 281, 2503-2524.
27. Finch, M.L.; Marquardt, J.U.; Yeoh, G.C.; Callus, B.A. Regulation of microRNAs and their role in liver development, regeneration and disease. Int. J. Biochem. Cell Biol. 2014, 54, 288-303.
28. Xie, H.; Lim, B.; Lodish, H.F. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009, 58,1050-1057.
29. Feng, Y.Y.; Xu, X.Q.; Ji, C.B.; Shi, C.M.; Guo, X.R.; Fu, J.F. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell. Physiol. Biochem. 2014, 34,1983-1997.
30. Lee, J.H.; Friso, S.; Choi, S.W. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014, 6, 3303-3325.
31. Cheung, O.; Puri, P.; Eicken, C.; Contos, M.J.; Mirshahi, F.; Maher, J.W.; Kellum, J.M.; Min, H.; Luketic, V.A.; Sanyal, A.J. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48,1810-1820.
32. Castro, R.E.; Ferreira, D.M.; Afonso, M.B.; Borralho, P.M.; Machado, M.V.; Cortez-Pinto, H.; Rodrigues, C.M. Mir-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 2013, 58,119-125.
33. Chang, H.C.; Guarente, L. Sirt1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 2014, 25, 138-145.
34. Ding, J.; Li, M.; Wan, X.; Jin, X.; Chen, S.; Yu, C.; Li, Y. Effect of mir-34a in regulating steatosis by targeting PPARa expression in nonalcoholic fatty liver disease. Sci. Rep. 2015, 5.
35. Wang, X.C.; Zhan, X.R.; Li, X.Y.; Yu, J.J.; Liu, X.M. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20,17914-17923.
36. Davalos, A.; Goedeke, L.; Smibert, P.; Ramirez, C.M.; Warrier, N.P.; Andreo, U.; Cirera-Salinas, D.; Rayner, K.; Suresh, U.; Pastor-Pareja, J.C. et al. Mir-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. USA 2011,108, 9232-9237.
37. Sacco, J.; Adeli, K. MicroRNAs: Emerging roles in lipid and lipoprotein metabolism. Curr. Opin. Lipidol. 2012, 23, 220-225.
38. Gori, M.; Arciello, M.; Balsano, C. MicroRNAs in nonalcoholic fatty liver disease: Novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed. Res. Int. 2014,741465.
39. Li, B.; Zhang, Z.; Zhang, H.; Quan, K.; Lu, Y.; Cai, D.; Ning, G. Aberrant mir199a-5p/caveolin1/PPARa axis in hepatic steatosis. J. Mol. Endocrinol. 2014, 53, 393-403.
40. Ye, H.; Liu, W. Transcriptional networks implicated in human nonalcoholic fatty liver disease. Mol. Genet. Genomics 2015,290,1793-1804.
41. Tsai, W.C.; Hsu, S.D.; Hsu, C.S.; Lai, T.C.; Chen, S.J.; Shen, R.; Huang, Y.; Chen, H.C.; Lee, C.H.; Tsai, T.F. et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Investig. 2012,122, 2884-2897.
42. Pogribny, I.P.; Starlard-Davenport, A.; Tryndyak, V.P.; Han, T.; Ross, S.A.; Rusyn, I.; Beland, F.A. Difference in expression of hepatic micrornas miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab. Investig. 2010, 90, 1437-1446.
43. Csak, T.; Bala, S.; Lippai, D.; Satishchandran, A.; Catalano, D.; Kodys, K.; Szabo, G. MicroRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015, 35, 532-541.
44. Dattaroy, D.; Pourhoseini, S.; Das, S.; Alhasson, F.; Seth, R.K.; Nagarkatti, M.; Michelotti, G.A.; Diehl, A.M.; Chatterjee, S. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G298-G312.
45. Loyer, X.; Paradis, V.; Henique, C.; Vion, A.C.; Colnot, N.; Guerin, C.L.; Devue, C.; On, S.; Scetbun, J.; Romain, M. et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARa expression. Gut 2015.
46. Li, S.; Chen, X.; Zhang, H.; Liang, X.; Xiang, Y.; Yu, C.; Zen, K.; Li, Y.; Zhang, C.Y. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J. Lipid Res. 2009, 50, 1756-1765.
47. Pineau, P.; Volinia, S.; McJunkin, K.; Marchio, A.; Battiston, C.; Terris, B.; Mazzaferro, V.; Lowe, S.W.; Croce, C.M.; Dejean, A. Mir-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA 2010,107, 264-269.
48. Ogawa, T.; Enomoto, M.; Fujii, H.; Sekiya, Y.; Yoshizato, K.; Ikeda, K.; Kawada, N. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012, 61, 1600-1609.
49. Callegari, E.; Elamin, B.K.; Giannone, F.; Milazzo, M.; Altavilla, G.; Fornari, F.; Giacomelli, L.; D’Abundo, L.; Ferracin, M.; Bassi, C.; et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012, 56,1025-1033.
50. Hur, W.; Lee, J.H.; Kim, S.W.; Kim, J.H.; Bae, S.H.; Kim, M.; Hwang, D.; Kim, Y.S.; Park, T.; Um, S.J. et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int. J. Biochem. Cell Biol. 2015, 64, 265-276.
51. Wu, H.; Ng, R.; Chen, X.; Steer, C.J.; Song, G. Microrna-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-SREBP1c pathway. Gut 2015.
52. Vinciguerra, M.; Sgroi, A.; Veyrat-Durebex, C.; Rubbia-Brandt, L.; Buhler, L.H.; Foti, M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (pten) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009, 49,1176-1184.
53. Hermeking, H. P53 enters the microRNA world. Cancer Cell 2007,12, 414-418.
54. Derdak, Z.; Villegas, K.A.; Harb, R.; Wu, A.M.; Sousa, A.; Wands, J.R. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J. Hepatol. 2013, 58, 785-791.
55. Sharma, H.; Estep, M.; Birerdinc, A.; Afendy, A.; Moazzez, A.; Elariny, H.; Goodman, Z.; Chandhoke, V.; Baranova, A.; Younossi, Z.M. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2013, 28,1410-1415.
56. Higuchi, H.; Gores, G.J. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284, G734-G738.
57. Ferreira, D.M.; Afonso, M.B.; Rodrigues, P.M.; Simao, A.L.; Pereira, D.M.; Borralho, P.M.; Rodrigues, C.M.; Castro, R.E. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol. Cell. Biol. 2014, 34, 1100-1120.
58. Cheng, G. Circulating mirnas: Roles in cancer diagnosis, prognosis and therapy. Adv. Drug Deliv. Rev. 2015, 81, 75-93.
59. Arrese, M.; Eguchi, A.; Feldstein, A.E. Circulating microRNAs: Emerging biomarkers of liver disease. Semin. Liver Dis. 2015, 35, 43-54.
60. Povero, D.; Eguchi, A.; Li, H.; Johnson, C.D.; Papouchado, B.G.; Wree, A.; Messer, K.; Feldstein, A.E. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS ONE 2014, 9, e113651.
61. Cermelli, S.; Ruggieri, A.; Marrero, J.A.; Ioannou, G.N.; Beretta, L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011, 6, e23937.
62. Yamada, H.; Ohashi, K.; Suzuki, K.; Munetsuna, E.; Ando, Y.; Yamazaki, M.; Ishikawa, H.; Ichino, N.; Teradaira, R.; Hashimoto, S. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin. Chim. Acta 2015, 446, 267-271.
63. Saha, B.; Momen-Heravi, F.; Kodys, K.; Szabo, G. MicroRNA cargo of extracellular vesicles from alcohol-exposed monocytes signals naive monocytes to differentiate into M2 macrophages. J. Biol. Chem. 2015.
64. Povero, D.; de Araujo Horcel, L.; Eguchi, A.; Johnson, C.; Kneiber, D.; Feldstein, A.E. MiR-128-3p is enriched in the liver of murine models of NASH and is a key contributor to liver fibrosis via modulation of hepatic stellate cell phenotype. In Proceedings of The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA, USA, 13-17 November 2015.
65. Pirola, C.J.; Fernandez Gianotti, T.; Castano, G.O.; Mallardi, P.; San Martino, J.; Mora Gonzalez Lopez Ledesma, M.; Flichman, D.; Mirshahi, F.; Sanyal, A.J.; Sookoian, S. Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015, 64, 800-812.
66. Wen, Y.; Han, J.; Chen, J.; Dong, J.; Xia, Y.; Liu, J.; Jiang, Y.; Dai, J.; Lu, J.; Jin, G. et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int. J. Cancer 2015, 137, 1679-1690.
67. Leti, F.; Malenica, I.; Doshi, M.; Courtright, A.; van Keuren-Jensen, K.; Legendre, C.; Still, C.D.; Gerhard, G.S.; DiStefano, J.K. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl. Res. 2015,166, 304-314.
68. Zarrinpar, A.; Gupta, S.; Maurya, M.R.; Subramaniam, S.; Loomba, R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: A prospective study. Gut 2015.
69. Sookoian, S.; Pirola, C.J. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS ONE 2013, 8, e58895.
70. Ebert, M.S.; Sharp, P.A. MicroRNA sponges: Progress and possibilities. RNA 2010, 16, 2043-2050.
71. Sayed, D.; Rane, S.; Lypowy, J.; He, M.; Chen, I.Y.; Vashistha, H.; Yan, L.; Malhotra, A.; Vatner, D.; Abdellatif, M. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 2008, 19,3272-3282.
72. Kosaka, N.; Takeshita, F.; Yoshioka, Y.; Hagiwara, K.; Katsuda, T.; Ono, M.; Ochiya, T. Exosomal tumor-suppressive microRNAs as novel cancer therapy: “Exocure” is another choice for cancer treatment. Adv. Drug Deliv. Rev. 2013, 65,376-382.
73. Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029-6033.
74. Wagenaar, T.R.; Zabludoff, S.; Ahn, S.M.; Allerson, C.; Arlt, H.; Baffa, R.; Cao, H.; Davis, S.; Garcia-Echeverria, C.; Gaur, R. et al. Anti-miR-21 suppresses hepatocellular carcinoma growth via broad transcriptional network deregulation. Mol. Cancer Res. 2015,13,1009-1021.
75. Wang, X.; Yu, B.; Ren, W.; Mo, X.; Zhou, C.; He, H.; Jia, H.; Wang, L.; Jacob, S.T.; Lee, R.J. et al. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J. Control. Release 2013,172,690-698.
76. Lindow, M.; Kauppinen, S. Discovering the first microRNA-targeted drug. J. Cell Biol. 2012,199, 407-412.
77. Ho, T.T.; Zhou, N.; Huang, J.; Koirala, P.; Xu, M.; Fung, R.; Wu, F.; Mo, Y.Y. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 2015,43, e17.